Skip to content
  • Report Harm
  • Newsletter
  • Press Room
Facebook Linkedin YouTube Instagram Twitter Spotify
Benzodiazepine Information Coalition
  • About BenzodiazepinesExpand
    • Benzo BasicsExpand
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • PrescribingExpand
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing RisksExpand
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • DeprescribingExpand
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing RisksExpand
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special PopulationsExpand
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About UsExpand
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • VolunteerExpand
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our ImpactExpand
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • ResourcesExpand
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Donate
Facebook Linkedin Twitter Instagram YouTube
Benzodiazepine Information Coalition

About Us

About Us

Our Mission

Educating about the potential adverse effects of benzodiazepines taken as prescribed.

ABOUT

Our Vision

We seek to break the stigma and raise awareness around prescribed benzodiazepine injury; provide a voice to the patients who are suffering, and facilitate research and access to competent, evidence-based medical care for those impacted by benzodiazepine-induced disability.

Support Us

They are the only people taking this issue seriously.

Jarret B., supporter
MEET OUR BOARD

Board of Directors

JC

Co-founder

Christy Huff, M.D.

Director

Stephen LaCorte, J.D.

​

General Advisory Board

Jane Macoubrie, Ph.D.
Brooke Monk
Krissy Tyrrell

Medical Advisory Board

James Berry, M.D.
Michael Bohan, M.D.
Gail Dawson, N.P.
Daniel F. Kripke, M.D.
Harold Gottlieb, M.D.
Patricia Halligan, M.D.
Nicole Lamberson, PA
Mark Leeds, D.O.
Elizabeth McCarthy, M.A.
Chris Paige, LCSW
Catherine Pittman, Ph.D.
Denise Senyk, M.D.
Sonja Styblo, LMSW
Jennifer Swantkowski, Ph.D., LCSW
Lisa Weldon, PMHNP-BC
Bobbi Wilkins, PA-C
Josef Witt-Doerring, M.D.
Jim Wright, M.D., Ph.D., FRCPC

In Memoriam

Raymond Armstrong, M.D.

Medical Advisory Board

Laurie Anne Campbell, RN

Co-founder
Board of Directors

Brad Verret

General Advisory Board


our Philosophy

Those suffering from a benzodiazepine induced disability lack adequate support as they struggle to understand the cause of their suffering and find treatment. They are told the problem doesn’t exist, that it is “all in their head”, and are given irrelevant tests resulting in misdiagnosis. Even when the cause of the injury is discovered, medical professionals often employ a classic “addiction” model that is inappropriate, and often disabling, for the more common problem of benzodiazepine dependence resulting from prescribed usage under medical supervision. Patients should not be forced to undergo the most deadly drug withdrawal known to science based on information gathered from the internet. Yet, since accurate information is not provided by most prescribers, websites devoted to benzodiazepine withdrawal often perform a life-saving function. Because some patients have little-to-no trouble taking benzodiazepines or coming off of them, the medical community assumes this experience is, or should be, the norm. We believe the responsible response is more research into the extremely variant impacts these drugs have on different people. A deficit of information has allowed the benzodiazepine epidemic to spread for decades, and urgently requires redress.

As we work to raise awareness of the risks of these drugs, we also seek to end the silence and stigma that has surrounded benzodiazepine induced disability for more than half a century. We seek change by educating and partnering with doctors, mental health providers, journalists, lawmakers, researchers, the benzodiazepine-impacted community, and society at large. Our deep personal understanding of the medical and social needs of the benzodiazepine impacted community informs all of our advocacy, from education and outreach, to lobbying for more research and the passage of informed consent laws that equip doctors and their patients with knowledge about the risks of using these drugs in a non-emergency context. Our work will continue until benzodiazepines are at the forefront of the national healthcare conversation; until patients are given adequate informed consent; until the rate of injury is significantly lowered; and until those cases that remain are understood and treated appropriately.

Who We Are

We are a group of patients and medical professionals who believe the over-prescription of benzodiazepines without proper warning has resulted in a growing national epidemic of benzodiazepine injury. While we understand and respect the value of these drugs when used appropriately, deep and widespread ignorance of their risks on the part of patients and prescribers has caused enormous and preventable suffering.

Our History

In the summer of 2016, Benzodiazepine Information Coalition formed as a U.S. non-profit organization dedicated to advocating for awareness and reform around the dangers of benzodiazepines, motivated by the years of watching benzodiazepine-injury support groups grow in membership by the thousands without any corresponding increase in attention from the public or medical community.

Why We Are Different

We are a group of patients and medical professionals who believe the over-prescription of benzodiazepines without proper warning has resulted in a growing national epidemic of benzodiazepine injury. While we understand and respect the value of these drugs when used appropriately, deep and widespread ignorance of their risks on the part of patients and prescribers has caused enormous and preventable suffering.

Because benzodiazepine-injury often does not fit common preconceptions about “side effects,” its victims all too often suffer for years in silence, shame, and confusion. Our advocacy is informed by our members’ personal experience, the scientific literature, and input from an advisory board comprised of physicians and other medical and mental health professionals.

Frequently
Asked
Questions

Some of our most frequently asked questions are answered here. Still can’t find an answer? Contact us. As an awareness organization, we do not offer any support services or guidance.

Contact Us

Benzodiazepine-injured patients, who grew tired of suffering in silence, decided to take action and spread awareness and advocacy for patients about the benzodiazepine epidemic.

Yes, BIC has 501(c)3 non-profit status.

We provide resources on our website, instigate media coverage and research, and educate medical professionals to break the silence around this epidemic and bring benzodiazepine injury to the forefront of medical discussion. We offer a benzodiazepine-cooperative prescriber list here.

We provide resources and recommended providers and support groups. We can not help individuals with specific cessation questions or support and do not answer these questions. For more on specific providers and support groups, see here.

Absolutely not. BIC exists to educate on the dangers of benzodiazepines only.

No. Due to the complicated and potentially disabling nature of benzodiazepine cessation, we firmly believe each patient has the right to fully informed consent in choosing if and when to take benzodiazepines and to choose a taper rate of their own when they decide to stop taking them.

We hope to prevent further patient injury by providing accurate information on the risks of benzodiazepine use. We understand that the most complicated and dangerous aspect of benzodiazepine use is cessation; the last thing we want to see is an outright ban on benzodiazepines that would result in thousands of unnecessary deaths.

Visit our Media Kit and contact us at bic@benzoinfo.com.

You can share our content on social media, fill out an FDA report, sign up to participate in a media interview, fundraise for us on Facebook and donate to us directly.

SAFE + EASY DONATIONS​

Support Benzodiazepine Awareness and Help Us:

  • Gain recognition of the existence and severity of prescribed benzodiazepine injury
  • Hold and participate in events to educate prescribers and the public
  • Push for policies that protect patients on benzodiazepines, whether they choose to remain on or taper off
  • Protect those presented with benzodiazepines as a treatment option by giving them true informed consent
  • Create more media awareness about this silent epidemic
  • Advocate for more prescriber training in safe prescribing and cessation
  • Fund research and show the need for future research that helps the harmed
Support Us

Contact Us

Inquiries
bic@benzoinfo.com

As an awareness organization, we do not offer any support services or guidance. See our resources for services and support.

Mailing Address
1042 Ft. Union Blvd, PMB 1030
Midvale, Utah 84047

Support BIC

We were formed to change the lack of knowledge in the public and the medical system. But we cannot do it alone. We rely solely on donations to operate. We are a 501(c)(3) tax exempt organization.

DONATE

Newsletter

Get notified about the latest studies, updates, calls to action, media stories, and other information.

*

IMPORTANT: After signing up, check your email to confirm we have the correct address. If you do not see an email, check your spam. We will add you to our newsletter once you complete this step to ensure delivery.

Notices

Benzodiazepine Information Coalition is a 501(c)3 tax exempt organization.

EIN: 81-3442343

Privacy Policy
Medical Disclaimer
Terms and Conditions
Free Charity Hosting by Kualo

Facebook Linkedin YouTube Instagram Twitter Spotify

© 2023 Benzodiazepine Information Coalition

Scroll to top
  • About Benzodiazepines
    • Benzo Basics
      • Ashton Manual
      • A Brief History Of Benzodiazepines
      • Class Actions and Lawsuits—and Reporting Harm 
      • FDA 2020 Benzodiazepine Boxed Warning
      • Medications and Supplements of Concern
      • Xanax Study Outcomes
    • Benzo Stories
    • Prescribing
      • Addiction vs Physical Dependence
      • Genetic Testing
      • Informed Consent
      • Low Dose Benzodiazepines
      • Mechanism of Action
      • Prescribing Statistics
      • Steps to Reduce Benzodiazepine Overprescribing
      • Therapeutic Actions
    • Prescribing Risks
      • Akathisia
      • Fluoroquinolones
      • Functional Brain Changes
      • Interdose Withdrawal
      • Paradoxical Reactions
      • Physical Dependence
      • Risks of Remaining on Benzodiazepines
      • Red Flags
      • Short-Term Risks
      • Side Effects
      • Suicide
      • Tolerance
    • Deprescribing
      • Ashton Manual
      • Tapering Strategies and Solutions
      • Detox, Cold Turkey, Abrupt Cessation
      • Estimates of Withdrawal
      • How To Find Tapering Help
      • Dosages Prevent Safe Withdrawal
      • Why Patients Shouldn’t Go To Detox or Rehab
    • Desprescribing Risks
      • Akathisia
      • Benzodiazepine Withdrawal Syndrome (BWS)
      • Forced Switching or Stopping
      • Functional Brain Changes
      • Kindling
      • Protracted Withdrawal Syndrome (PWS)
      • Suicide
      • Withdrawal & Post Withdrawal Symptoms
    • Special Populations
      • Benzodiazepines and PTSD
      • Celebrities
      • COVID-19
      • Elderly
      • Women
      • Incarcerated Population
      • Substance Use Disorders
  • About Us
    • Our Mission
    • Board Members and Advisors
    • Press Room
    • Receive Our Newsletter
    • FAQs
    • Volunteer
      • Informed Consent Policy
      • FDA Reporting Program
      • Share Your Story!
      • Media Interview List Registration
    • Contact Us
  • Our Impact
    • Media Outreach
    • Podcasts
    • Programs and Projects
    • Research and Publications
    • Speaking and Events
    • Quarterly Updates
    • Upcoming Events
  • Resources
    • Ashton Manual
    • Benzodiazepine Tapering Strategies and Solutions
    • Financial and Disability Information
    • How To Find Tapering Help
    • Support
    • Information
    • Benzodiazepine Cooperative Providers
  • Blog
  • Donate
Search
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset